Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial

Simply Wall St.02-01

Intellia Therapeutics (NTLA) attracted investor attention after the FDA removed the clinical hold on its MAGNITUDE-2 Phase 3 trial. This decision allows enrollment to resume under tighter liver safety...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608100299?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-01 13:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608100299","market":"nz","top_or_hot":-1,"title":"Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial","media":"Simply Wall St.","content":"<div>\n<p>Intellia Therapeutics (NTLA) attracted investor attention after the FDA removed the clinical hold on its MAGNITUDE-2 Phase 3 trial. This decision allows enrollment to resume under tighter liver safety...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/assessing-intellia-therapeutics-ntla-valuation-after-fda-lif\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-01 13:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/assessing-intellia-therapeutics-ntla-valuation-after-fda-lif><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Intellia Therapeutics (NTLA) attracted investor attention after the FDA removed the clinical hold on its MAGNITUDE-2 Phase 3 trial. This decision allows enrollment to resume under tighter liver safety...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/assessing-intellia-therapeutics-ntla-valuation-after-fda-lif\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861559042.SGD","symbol_name":"日兴方舟颠覆性创新基金B SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/assessing-intellia-therapeutics-ntla-valuation-after-fda-lif","article_id":"2608100299","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/assessing-intellia-therapeutics-ntla-valuation-after-fda-lif","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608100299","pubTimestamp":1769923184,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Intellia Therapeutics (NTLA) attracted investor attention after the FDA removed the clinical hold on its MAGNITUDE-2 Phase 3 trial. This decision allows enrollment to resume under tighter liver safety monitoring protocols.\nSee our latest analysis for Intellia Therapeutics.\nThe FDA decision arrives after a sharp run, with a 30 day share price return of 42.78% and a year to date share price return of 42.78%, yet the 3 year total shareholder return of 69.58% and 5 year total shareholder return...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4585":"ETF&股票定投概念","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4556":"基因编辑","BK4139":"生物科技","NTLA":"Intellia Therapeutics Inc","BK4588":"碎股","BK4535":"淡马锡持仓"},"translate_title":"FDA解除MAGNITUDE-2试验暂停后评估Intellia Therapeutics(NTLA)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1.5},"content_text":"Intellia Therapeutics (NTLA) attracted investor attention after the FDA removed the clinical hold on its MAGNITUDE-2 Phase 3 trial. This decision allows enrollment to resume under tighter liver safety monitoring protocols. See our latest analysis for Intellia Therapeutics. The FDA decision arrives after a sharp run, with a 30 day share price return of 42.78% and a year to date share price return of 42.78%, yet the 3 year total shareholder return of 69.58% and 5 year total shareholder return of 81% highlight how long term holders have still seen substantial value erosion despite the recent bounce. If this kind of regulatory catalyst has your attention, it may be worth scanning other healthcare stocks that could be reshaped by upcoming trial readouts and approvals. With Intellia now cleared to restart MAGNITUDE-2 and the share price already up 42.78% over 30 days, the key question is whether the current US$13.15 price still undervalues the story or if the market is already pricing in future growth. AdvertisementMost Popular Narrative: 41% Undervalued The most followed narrative puts Intellia’s fair value at $22.27 against the last close of $13.15, framing the recent FDA decision within a much bigger long term story.  Rapid technological and regulatory advancements in gene-editing, including increased healthcare investments, accelerating review pathways, and support for first in class CRISPR therapies, create a favorable environment for Intellia's platform to secure approvals, forge additional partnership/licensing opportunities, and achieve sustainable, recurring non dilutive revenues through both commercialization and collaborations, increasing top line growth and earnings potential.  Read the complete narrative. Curious what assumptions sit behind that gap between fair value and today’s price? Revenue compounding, margin shifts, and a future earnings multiple all play a part. The full narrative lays out how those moving pieces fit together, and which numbers have to line up for that valuation to hold. Result: Fair Value of $22.27 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you also need to weigh risks such as high R&D spend with ongoing cash burn, as well as the possibility that competition in ATTR and HAE limits future uptake. Find out about the key risks to this Intellia Therapeutics narrative. Another View: Rich Sales Multiple, Same Stock The community narrative leans on a fair value of $22.27, but the market is sending a mixed signal. Intellia trades on a P/S of 26.5x, more than double the US Biotechs average of 11.6x and above its own fair ratio of 0x. This points to meaningful valuation risk if sentiment cools. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:NTLA P/S Ratio as at Feb 2026 Build Your Own Intellia Therapeutics Narrative If you look at the numbers and come to a different conclusion, that is the point. The tools are there so you can build your own view in under a few minutes; all you need to do is hit Do it your way. A great starting point for your Intellia Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? If you stop with just one stock, you miss out on other angles the market is offering right now. Put the Screener to work for you.  Spot potential value opportunities faster by scanning these 875 undervalued stocks based on cash flows that might not yet be front of mind for most investors. Zero in on cutting edge opportunities tied to artificial intelligence by checking out these 24 AI penny stocks before the crowd turns its attention there. Balance growth potential with income by reviewing these 12 dividend stocks with yields > 3% that combine yield with the backing of listed businesses.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608100299","isCrawlerRequest":true}